Pilots

Pilot Overview

Multiparameter INsight platform for Therapeutic nanoparticles

MINT

Bluepharma, a leading pharmaceutical company, faces a key challenge in characterizing complex therapeutic nanoparticles. As it advances lipid-based nanoparticles and polymeric carriers, the need for rapid, reliable, non-destructive analytics grows urgent. Traditional tools are slow, destructive, and limited. To stay competitive and meet EMA/FDA expectations, Bluepharma must adopt real-time, multiparameter solutions that speed formulation, ensure quality, and support innovation.

Open call

OC1 EIC Awardee + Buyer (wave1)

Sector

Health and Life Sciences

Buyer information

Bluepharma

Bluepharma is a globally recognized pharmaceutical company headquartered in Portugal, with operations spanning over 40 countries. With state-of-the-art facilities certified by international regulatory Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. authorities (including EMA and FDA), Bluepharma offers end-to-end capabilities from R&D to industrial-scale manufacturing on oral solids and complex injectable dosage forms.

Solver information

iLoF – Intelligent Lab on Fiber

iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery and development. Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster.

Solution

Our solution — Optomics® — is a proprietary platform that redefines nanoparticle characterization by combining advanced photonics and artificial intelligence in a compact, real-time analytical system. 

Unlike conventional techniques such as DLS, NTA, or TEM—which require destructive sample prep, lengthy analysis, and deliver only single-parameter outputs—Optomics® enables simultaneous, label-free, and non-destructive multiparameter analysis. In one streamlined workflow, it provides insights on particle size distribution, concentration, payload distribution, and molecular profiling, all without compromising sample integrity or relying on specialized reagents. 

Featuring a modular design and cloud-enabled architecture, Optomics® integrates seamlessly into R&D and manufacturing settings. By reducing analysis time, strengthening batch consistency monitoring, and generating richer datasets, Optomics® offers a transformative alternative to state-of-the-art methods, accelerating development and ensuring product quality.

Pilot specific details

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus ligula elit, suscipit eget gravida ut, vehicula et quam. Nam dolor lectus, sollicitudin eget pulvinar ac, vestibulum sit amet leo. Cras ut lacinia purus. Ut vitae tincidunt elit, dignissim dignissim eros. Integer viverra imperdiet magna ac sodales. Phasellus tristique gravida justo, eget finibus enim egestas sit amet. Mauris maximus ligula sem. Morbi feugiat eget felis ac placerat. Aenean sit amet quam in dolor efficitur imperdiet vitae eu dolor.

€123.4M

Lorem ipsum

38 SMEs

Lorem ipsum

60.000€

Lorem ipsum

50 Pilots

Lorem ipsum

Testimonials

Name Surname

COMPANY

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus ligula elit, suscipit eget gravida ut, vehicula et quam. Nam dolor lectus, sollicitudin eget pulvinar ac, vestibulum sit amet leo. Cras ut lacinia purus. Ut vitae tincidunt elit, dignissim dignissim eros.

Name Surname

COMPANY

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus ligula elit, suscipit eget gravida ut, vehicula et quam. Nam dolor lectus, sollicitudin eget pulvinar ac, vestibulum sit amet leo. Cras ut lacinia purus. Ut vitae tincidunt elit, dignissim dignissim eros.

Results

€123.4M

Lorem ipsum

38 SMEs

Lorem ipsum

60.000€

Lorem ipsum

50 Pilots

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus ligula elit, suscipit eget gravida ut, vehicula et quam. Nam dolor lectus, sollicitudin eget pulvinar ac, vestibulum sit amet leo. Cras ut lacinia purus. Ut vitae tincidunt elit, dignissim dignissim eros. Integer viverra imperdiet magna ac sodales. Phasellus tristique gravida justo, eget finibus enim egestas sit amet. Mauris maximus ligula sem. Morbi feugiat eget felis ac placerat. Aenean sit amet quam in dolor efficitur imperdiet vitae eu dolor.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus ligula elit, suscipit eget gravida ut, vehicula et quam. Nam dolor lectus, sollicitudin eget pulvinar ac, vestibulum sit amet leo. Cras ut lacinia purus. Ut vitae tincidunt elit, dignissim dignissim eros. Integer viverra imperdiet magna ac sodales. Phasellus tristique gravida justo, eget finibus enim egestas sit amet. Mauris maximus ligula sem. Morbi feugiat eget felis ac placerat. Aenean sit amet quam in dolor efficitur imperdiet vitae eu dolor.